![]() |
市場調査レポート
商品コード
1289658
無血清市場- 世界の産業規模、シェア、動向、機会、予測、2017年~2027年:メディアタイプ別、エンドユーザー別、企業別、地域別分析Serum Free Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Media Type, By End User, By company and By Region |
||||||
カスタマイズ可能
|
無血清市場- 世界の産業規模、シェア、動向、機会、予測、2017年~2027年:メディアタイプ別、エンドユーザー別、企業別、地域別分析 |
出版日: 2023年06月01日
発行: TechSci Research
ページ情報: 英文 113 Pages
納期: 2~3営業日
|
無血清の世界市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されています。
主な要因としては、感染症や慢性疾患の有病率の上昇、がん治療のための細胞治療への需要、研究開発活動の増加などが挙げられ、これらは市場の成長を後押ししています。無血清培地は、血清がない状態で特定の細胞種を培養したり、特定の用途を実行することを目的とした培地です。無血清培地(SFM)の使用は、交絡変数が可能な限りなく、定義された一連の条件で細胞培養を行うことを可能にする不可欠なツールを意味します。市場の成長を支えるその他の要因としては、様々な組換えタンパク質や培養タイプに対する需要の増加、希少疾患の患者登録の拡大、より容易な下流処理、新規治療薬開発のための研究開発の拡大、バイオ医薬品産業とバイオ医薬品生産の拡大、先端技術の採用、研究開発活動の活発化などが挙げられます。また、合併、提携、買収などの戦略的成長の増加が市場の成長を強化しています。例えば、2019年、ザルトリウスは細胞培養培地専門バイオ企業の過半数の株式取得を宣言しました。
心血管疾患、糖尿病、性病、呼吸器感染症、院内感染(院内感染)などの感染症や慢性疾患の罹患率の上昇が、世界の市場の成長を後押ししています。ライフスタイルの変化、社会的行動、不健康な食事の選択のために、人々はこれらの病気に苦しんでおり、これが市場の成長を促進しています。世界保健機関(WHO)によると、感染症により年間約1,700万人が死亡しています。老年人口は、整形外科疾患、インフルエンザ、心血管疾患、結核、神経疾患、院内感染(院内感染)など、これらの病気にかかりやすいです。全米腎臓財団によると、世界中で65歳から74歳の女性の4人に1人、男性の5人に1人が慢性腎臓病を患っています。無血清培地は、細胞傷害性リンパ球(CTL)、IL-2、IL-4、単球などの免疫学的細胞を産生するために、多くのタイプの懸濁培養や付着培養に使用され、様々なワクチンの生産に利用されています。
無血清培地は、感染症のリスクが低い、汚染物質が少ない、干渉成分のリスクが低いなどの特性があるため、無血清培地を採用するバイオ医薬品生産が増加しており、市場の成長を促進しています。様々な疾病の増加により、これらの疾病を治療するための需要も急増しています。これは、バイオ医薬品の高い効能が治療の選択肢となり、バイオ医薬品の生産が増加しているためです。このように、バイオ医薬品産業の拡大と生産量の増加が市場の成長を増大させています。例えば、2019年に医薬品評価研究センターは48の新薬を承認したが、そのうち28%は生物製剤でした。
TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です:
The global serum-free market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the rising prevalence of infectious and chronic diseases, demand for cell therapies for cancer treatment, and an increase in R&D activities that are impelling the growth of the market. Serum-free media are media intended to grow a specific cell type or execute a specific application in the absence of serum. The use of serum-free media (SFM) signifies an essential tool that enables cell culture to be performed with a defined set of conditions as free as possible of confounding variables. The other factors supporting the market's growth are, increasing demand for various recombinant proteins and types of culture, expanding patient registry for rare diseases, easier downstream processing, growing research & development for the development of novel therapeutic drugs, expansion of biopharmaceutical industries and biopharma production, adoption of advanced technology, and rise in research and development activities. Also, the increasing strategic growth, such as mergers, collaborations, and acquisitions, is strengthening the growth of the market. For instance, in 2019, Sartorius declared the acquisition of a majority stake in cell culture media specialist biological companies.
The rising incidences of infectious and chronic diseases such as cardiovascular diseases, diabetes, STD, respiratory infections, and nosocomial (hospital-acquired) infections are bolstering the growth of the market globally. Owing to lifestyle changes, social behavior, and unhealthy eating choices, people are suffering from these diseases, which propels the growth of the market. According to the World Health Organization (WHO), infectious diseases kill around 17 million people a year. Geriatric populations are highly prone to these diseases, such as orthopedic diseases, influenza, cardiovascular diseases, tuberculosis, neurological disorders, and nosocomial (hospital-acquired) infections. According to the National Kidney Foundation, one in four women and one in five men aged between 65 to 74 years have chronic kidney disease across the globe. Serum-free media is used in numerous types of suspension and adherent cultures to produce immunological cells such as cytotoxic lymphocytes (CTLs), IL-2, IL-4, and monocytes, which are utilized in the production of a variety of vaccines.
The increase in biopharmaceutical production with the rise in adoption of serum-free media, due to its properties such as lower risks of infectious agents, fewer contaminants, and lower risk of interfering components, is facilitating the growth of the market. Owing to the rising incidences of various diseases, the demand to treat these diseases is also surging. This is attributed to the high potency of biopharmaceuticals, which enables them to be the choice of treatment, thus increasing biopharmaceutical production. Thus, the expansion of biopharmaceutical industries and the rise in production are augmenting the growth of the market. For Instance, in 2019, the Center for Drug Evaluation and Research approved 48 new drugs in which, 28% of which were biologics.
The global serum-free market is segmented into media type, end user, and company. Based on the media type, the market is segmented into common serum-free, xeno-free, chemically defined, protein-free, and others. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research organizations, contract research organizations, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of research and development and clinical trial programs in the country.
Corning Incorporated, Lonza Group AG, Merck KgaA, Sartorius AG, Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation, PromoCell GmbH, Athena Environmental Sciences, Inc., STEMCELL Technologies Inc., Danaher Corporation, R&D Systems, Inc., Sino Biological, Inc., HiMedia Laboratories, LLC, PAN-Biotech GmbH, and MP Biomedicals, LLC are some of the leading companies operating in the market.
In this report, global serum-free market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Serum Free Market
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: